Anavex Life Sciences Corp (AVXL)

[powerwalker]

This is what the Company stated in its 2023 Q1 PR:

On December 1st, 2022, the Company announced, in a late breaking oral presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022, the top line data of its randomized, double-blind, multicenter, placebo-controlled Phase 2b/3 study ANAVEX®2-73-AD-004 for the treatment of early Alzheimer’s disease. The trial met both its co-primary and key secondary endpoints, showing statistically significant and clinically meaningful improvement in cognition and function as measured by ADAS-Cog, ADCS-ADL, and CDR-SB, respectively.

https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2023-first-quarter-financial-results

So, did Anavex lie in its PR that it met the ADCS-ADL endpoint? Was this retracted later to correct the Q1 PR? TIA

ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!